A Phase 1 interventional study of Oral semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-11.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 156th largest by enrollment, is one of 10 that started in 2021, is one of 41 in phase 1, and was the 84th registered.
10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Emory University · Sites in United States
Ages 65+ · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–64 · Healthy volunteers
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–70
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
163 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 14 · Phase 3 58 · Phase 4 40
First in 2007; this study’s year is marked. 10 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 104 across the 163 interventional studies. Of the 109 that completed or were terminated, 54 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 163 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 416th largest by enrollment of the 428 interventional ones that give a count, is one of 26 that started in 2021, is one of 129 in phase 1, and was the 529th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
14 of the studies testing semaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06461377The First Affiliated Hospital with Nanjing Medical UniversityThe Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
Participants in the study, will receive the study drug once daily for 10 days in tablet form for oral (by mouth) intake. On day 1 to 5 the tablet will contain 3 mg semaglutide, and on day 6-10 the tablet will contain 7 mg semaglutide.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive oral semaglutide once daily for a total of 10 days: 3 mg for 5 days followed by 7 mg for 5 days.
Drug: Oral semaglutide
Oral semaglutide once daily for a total of 10 days
Area under the semaglutide milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,milk)
nmol\*h/L
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the salcaprozate sodium (SNAC) milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,milk)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Average semaglutide milk concentration during a dosing interval after the 10th dosing (Cavg,sema,D10,milk)
nmol/L
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,milk)
nmol/L
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Minimum semaglutide milk concentration during a dosing interval after the 10th dosing (Cmin,sema,D10,milk)
nmol/L
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum semaglutide milk concentration during a dosing interval after the 10th dosing (tmax,sema,D10,milk)
Hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant semaglutide dose
mg/kg/day
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Relative daily infant semaglutide dose
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC milk concentration during a dosing interval after the 10th dosing (Cavg,SNAC,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC milk concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC milk concentration during a dosing interval after the 10th dosing (Cmin,SNAC,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC milk concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,milk)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC dose
ng/kg/day
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Relative daily infant SNAC dose
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E494 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,milk)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cavg,E494,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E494 milk concentration during a dosing interval after the 10th dosing (Cmin,E494,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E494 milk concentration after the 10th dosing (tmax,E494,D10,milk)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E494 dose
ng/kg/day
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E506 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,milk)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cavg,E506,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E506 milk concentration during a dosing interval after the 10th dosing (Cmin,E506,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E506 milk concentration after the 10th dosing (tmax,E506,D10,milk)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E506 dose
ng/kg/day
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1245 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,milk)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cavg,E1245,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E1245 milk concentration during a dosing interval after the 10th dosing (Cmin,E1245,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1245 milk concentration after the 10th dosing (tmax,E1245,D10,milk)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E1245 dose
ng/kg/day
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1246 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,milk)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cavg,E1246,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E1246 milk concentration during a dosing interval after the 10th dosing (Cmin,E1246,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1246 milk concentration in milk after the 10th dosing (tmax,E1246,D10,milk)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E1246 dose
ng/kg/day
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1247 milk concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,milk)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Average SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cavg,E1247,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Minimum SNAC metabolite E1247 milk concentration during a dosing interval after the 10th dosing (Cmin,E1247,D10,milk)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1247 milk concentration after the 10th dosing (tmax,E1247,D10,milk)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Estimated daily infant SNAC metabolite E1247 dose
ng/kg/day
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the semaglutide plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,sema,D10,plasma)
nmol\*h/L
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (Cmax,sema,D10,plasma)
nmol/L
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum semaglutide plasma concentration during a dosing interval after the 10th dosing (tmax,sema,D10,plasma)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,SNAC,D10,plasma)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC plasma concentration during a dosing interval after the 10th dosing (Cmax,SNAC,D10,plasma)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC plasma concentration during a dosing interval after the 10th dosing (tmax,SNAC,D10,plasma)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E494 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E494,D10,plasma)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (Cmax,E494,D10,plasma)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E494 plasma concentration during a dosing interval after the 10th dosing (tmax,E494,D10,plasma)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E506 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E506,D10,plasma)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (Cmax,E506,D10,plasma)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E506 plasma concentration during a dosing interval after the 10th dosing (tmax,E506,D10,plasma)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1245 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1245,D10,plasma)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1245,D10,plasma)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1245 plasma concentration during a dosing interval after the 10th dosing (tmax,E1245,D10,plasma)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1246 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1246,D10,plasma)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1246,D10,plasma)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1246 plasma concentration during a dosing interval after the 10th dosing (tmax,E1246,D10,plasma)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Area under the SNAC metabolite E1247 plasma concentration-time curve during a dosing interval after the 10th dosing (AUC0-24h,E1247,D10,plasma)
ng\*h/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (Cmax,E1247,D10,plasma)
ng/mL
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Time to maximum SNAC metabolite E1247 plasma concentration during a dosing interval after the 10th dosing (tmax,E1247,D10,plasma)
hours
Time frame: From 0 to 24 hours after the 10th dosing (day 10)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in May 2023, 20 months.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 20 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide